Who is sponsoring NCT06270641?

NCT06270641 is sponsored by University of Washington.

What drugs are being tested in NCT06270641?

Interventions in NCT06270641: ExerciseRx intervention.

What condition does NCT06270641 study?

NCT06270641 studies Multiple Sclerosis (MS), Fatigue, Physical Inactivity.

Is NCT06270641 still recruiting?

NCT06270641 is currently recruiting now. Last updated 22 February 2024.

Last reviewed 2024-02-22 · How we verify

NCT06270641

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Increasing Physical Activity for Adults With Multiple Sclerosis (MS)

Recruiting now NA Last updated 22 February 2024

What this trial tests

NA trial testing ExerciseRx intervention in Multiple Sclerosis (MS) in 106 participants. Currently enrolling.

Timeline

16 February 2024

Primary endpoint
30 April 2025

30 September 2026

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	106
Start date	16 February 2024
Primary completion	30 April 2025
Estimated completion	30 September 2026
Sites	1 location across United States

Drugs / interventions tested

ExerciseRx intervention

Conditions studied

Multiple Sclerosis (MS) — all drugs for Multiple Sclerosis (MS) →
Fatigue — all drugs for Fatigue →
Physical Inactivity — all drugs for Physical Inactivity →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Multiple Sclerosis (MS) or Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to advance the scientific understanding and potential future implementation of physical activity promotion by testing the efficacy of a phone-based app for increasing activity in insufficiently active patients with multiple sclerosis (MS).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Increasing Physical Activity via Provider Support and Engagement Using a Digital Health Platform in Adults With Multiple Sclerosis: Protocol for a Randomized Controlled Trial.
Ehde DM, Simmons SB, Alschuler KN, Herring TE, et al · · 2025 · PMID 41268963 · DOI 10.2196/72213

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis (MS)

Currently open trials in the same condition.

NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media · Phase 1 · recruiting
NCT06869278 — A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases · Phase 1 · recruiting
NCT06053749 — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimest · active not recruiting
NCT06157086 — Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France · active not recruiting
NCT05359653 — Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy · Phase 1, PHASE2 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06270641 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 22 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06270641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing